Optimizing an effective combination of the new microtubule-targeting agent lisavanbulin with standard-of-care therapy for glioblastoma in patient-derived xenograft preclinical models

Neuro Oncol. 2022 Mar 12;24(3):396-397. doi: 10.1093/neuonc/noab278.

Author

Alain Charest^{1

2}

Affiliations

¹ Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
² Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antineoplastic Agents, Alkylating / therapeutic use
Brain Neoplasms* / drug therapy
Glioblastoma* / drug therapy
Heterografts
Humans
Microtubules

Substances

Antineoplastic Agents, Alkylating